Innate Pharma provides update on AstraZeneca-sponsored Interlink-1 Phase 3 study
Innate Pharma to participate in upcoming investor conference
Second Innate Pharma NK Cell Engager Selected by Sanofi as drug candidate for development
Innate Pharma to participate in upcoming investor conference
Innate Pharma announces IPH5201 Phase 2 study in lung cancer
Outcome of Innate Pharma's 2022 Annual General Meeting
Innate Pharma to participate in upcoming investor conferences
Innate Pharma reports First Quarter 2022 financial results and business update
Number of shares and voting rights of Innate Pharma as of May 1, 2022
Innate Pharma establishes an At-The-Market ("ATM") program on Nasdaq
